Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls

Acrivon Therapeutics Inc. (NASDAQ:ACRV) on Thursday shared updates regarding the Phase 2 ACR-368 program and initial clinical data from the ACR-2316 Phase 1 study.ACR-368 DataIn Arm 1 of the ACR-368 Phase 2b registrational-intent trial in endometrial cancer, an updated interim analysis showed an overall response rate (ORR) of 39%. In subjects with over two prior lines of therapy, the ORR was 44%.Based on data that showed higher response rates in subjects with serous endometrial cancer (also called uterine s ...